Related Experiment Video
Updated: Aug 11, 2025

Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins
Published on: January 18, 2019
Current Understanding of Clinical Manifestations of COVID-19 in Glomerular Disease
Allison Shimmel1, Salma Shaikhouni2, Laura Mariani2
1College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, USA.
Insights
COVID-19 (SARS-CoV-2) can cause new glomerular disease or relapse in patients with existing kidney conditions. Management of immunosuppression in these patients during the pandemic presents unique challenges requiring further research.
Area of Science:
- Nephrology
- Infectious Diseases
- Immunology
Background:
- The COVID-19 pandemic caused by SARS-CoV-2 has a significant mortality rate.
- Limited information exists on the specific impact of SARS-CoV-2 infection on patients with glomerular diseases.
- Understanding the evolving effects of SARS-CoV-2 on glomerular health is crucial.
Purpose of the Study:
- To review and summarize current data on COVID-19 manifestations in patients with pre-existing and de novo glomerular disease.
- To explore the potential mechanisms of kidney injury in the context of SARS-CoV-2 infection.
- To highlight the challenges in managing immunosuppression for glomerular disease patients during the pandemic.
Main Methods:
- Literature review of published data on COVID-19 and glomerular disease.
- Analysis of proposed mechanisms for kidney injury, proteinuria, and hematuria.
- Discussion of case reports and clinical observations.
Main Results:
- SARS-CoV-2 infection can trigger glomerular disease relapse or new-onset disease, including IgA nephropathy, ANCA vasculitis, and collapsing glomerulopathy.
- Kidney injury may result from direct tubular injury, hemodynamic instability, hypoxic injury, or a cytokine storm.
- The role of direct viral invasion and podocytopathy is under investigation.
- Collapsing glomerulopathy has been observed in SARS-CoV-2 cases, particularly in individuals with specific APOL1 alleles.
Conclusions:
- SARS-CoV-2 infection can induce de novo glomerular disease, with mechanisms still under investigation.
- Managing patients with existing glomerular disease during COVID-19 poses significant challenges, particularly concerning immunosuppression.
- Further research is essential to guide clinical decision-making for these patients.
Background:
The novel coronavirus disease (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an evolving pandemic with significant mortality. Information about the impact of infection on glomerular disease patients in particular has been lacking. Understanding the virus's effect in glomerular disease is constantly changing. This review article summarizes the data published thus far on COVID-19 and its manifestations in pre-existing and de novo glomerular disease.
Summary:
While patients with glomerular disease may be at higher risk of severe COVID-19 due to their immunosuppressed status, some data suggest that a low amount of immunosuppression may be helpful in mitigating the systemic inflammatory response which is associated with high mortality rates in COVID-19. There have been a few case reports on COVID-19 causing glomerular disease relapse in patients. Multiple mechanisms have been proposed for kidney injury, proteinuria, and hematuria in the setting of COVID-19. More commonly, these are caused by direct tubular injury due to hemodynamic instability and hypoxic injury. However, the cytokine storm induced by COVID-19 may trigger common post-viral glomerular disease such as IgA nephropathy, anti-GBM, and ANCA vasculitis that have also been described in COVID-19 patients. Collapsing glomerulopathy, a hallmark of HIV-associated nephropathy, is being reported SARS-CoV-2 cases, particularly in patients with high-risk APOL1 alleles. Direct viral invasion of glomerular structures is hypothesized to cause a podocytopathy due to virus's affinity to ACE2, but evidence for this remains under study.
Key Messages:
Infection with SARS-CoV-2 may cause glomerular disease in certain patients. The mechanism of de novo glomerular disease in the setting of COVID-19 is under study. The management of patients with existing glomerular disease poses unique challenges, especially with regard to immunosuppression management. Further studies are needed to inform clinician decisions about the management of these patients during the COVID-19 pandemic.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Nephrotic Syndrome I : Introduction
Acute Kidney Injury III: Clinical Manifestations
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury II: Pathophysiology

